HGCSG 1403: phase I trial of oxaliplatin /irinotecan /S-1 (OX-IRIS) for unresectable pancreatic cancer

  • Kawamoto Y
  • Yuki S
  • Hayashi H
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background: FOLFIRINOX has become one of the standard treatment for unresectable pancreatic cancer (PC) with distant metastasis. OX-IRIS is the combination therapy of oxaliplatin (L-OHP), irinotecan (IRI) and S-1. It is the useful treatment to dispense with a continuous infusion of 5FU by administering S-1 orally. For establishing OXIRIS therapy as a new standard treatment, we planned this study for evaluating dose limiting toxicity (DLT) and maximum tolerated dose (MTD)(UMIN ID: 000017002). Methods: This study was carried out as a multicenter phase I study. Chemotherapy naïve patients with unresectable PC were included. L-OHP and IRI were administered on day1 and 15, and S-1 was taken twice a day in day1-14, and then 14 days were rest for 1 cycle. The primary endpoints were the frequency of DLT and estimating of MTD. Secondary endpoints were safety, response rate, progression-free survival (PFS) and overall survival. Results: Between January 2016 and August 2017, 13 cases were enrolled. The patients' backgrounds were median age 62, man /woman; 9/4, the primary tumor sites head / body and tail; 8/5, ECOG PS 0/1; 7/6, UR-LA /UR-M; 4/9. Two of five enrolled in level 0 (L-OHP: 85 mg/m2, IRI: 100 mg/m2, S-1: 80 mg/m2) had DLT. In two of eight in level -1 (L-OHP: 65 mg/m2, IRI: 100 mg/m2, S-1: 80 mg/m2), it was impossible to evaluate DLT because the treatment of one cycle was not accomplished. And one of remaining six had DLT. At level 0, 100% of cases had anemia and fatigue, 80% anorexia, diarrhea, peripheral sensory neuropathy, 60% platelet count decrease. At level -1, 100% had anemia, 75% nausea and fatigue, 63% anorexia. Response rate was 10% and disease control rate was 70% in ten cases with evaluable lesion. Median PFS was 4.1 months (95%C.I.; 0.0-8.6 months). Conclusions: In this study, MTD was estimated to be level 0, and determined recommended dose is level -1 for the planned future study. We are going to evaluate efficacy and safety in a phase II study.

Cite

CITATION STYLE

APA

Kawamoto, Y., Yuki, S., Hayashi, H., Nakano, S., Sawada, K., Muranaka, T., … Komatsu, Y. (2018). HGCSG 1403: phase I trial of oxaliplatin /irinotecan /S-1 (OX-IRIS) for unresectable pancreatic cancer. Annals of Oncology, 29, vii63. https://doi.org/10.1093/annonc/mdy374.051

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free